Friday, June 19

Browsing: PolatuzumabRituximab

Treatments

Polatuzumab/Rituximab Display Tolerability in Frail/Older DLBCL Groups

By NewsCancerJune 12, 20260

Combination regimens containing rituximab (Rituxan) plus dose-reduced cyclophosphamide, vincristine, doxorubicin, and prednisone (R-mini-CHOP) or polatuzumab vedotin-piiq (Polivy) and rituximab plus…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

What Was Really Behind My “Laziness” and What I Know Now

Spatially interpretable artificial intelligence framework to tailored neoadjuvant dual HER2 blockade in HER2-positive breast cancer

In vivo CRISPR knockout screen identifies Polr1a as a key driver and a potential therapeutic target for melanoma metastasis

Browsing: PolatuzumabRituximab

Polatuzumab/Rituximab Display Tolerability in Frail/Older DLBCL Groups

What Was Really Behind My “Laziness” and What I Know Now

Spatially interpretable artificial intelligence framework to tailored neoadjuvant dual HER2 blockade in HER2-positive breast cancer

In vivo CRISPR knockout screen identifies Polr1a as a key driver and a potential therapeutic target for melanoma metastasis

I had to crowdfund my cancer treatment in Australia’s ‘universal’ health-care system

What Was Really Behind My “Laziness” and What I Know Now

Spatially interpretable artificial intelligence framework to tailored neoadjuvant dual HER2 blockade in HER2-positive breast cancer

In vivo CRISPR knockout screen identifies Polr1a as a key driver and a potential therapeutic target for melanoma metastasis

I had to crowdfund my cancer treatment in Australia’s ‘universal’ health-care system

Latest Post

What Was Really Behind My “Laziness” and What I Know Now

Spatially interpretable artificial intelligence framework to tailored neoadjuvant dual HER2 blockade in HER2-positive breast cancer

In vivo CRISPR knockout screen identifies Polr1a as a key driver and a potential therapeutic target for melanoma metastasis

Subscribe to Updates

What's Hot

Browsing: PolatuzumabRituximab